Table 4.
Characteristics of study group with underlying medical conditions by the number of COVID-19 vaccine doses received.
| Underlying Conditions | Total | Received Only One Vaccine Dose N (%) |
Received Two Vaccine Doses N (%) |
Received Three Vaccine Doses N (%) |
p-Value |
|---|---|---|---|---|---|
| Obesity (BMI > 30) | 49,993 | 3742 (7.5%) | 7020 (14%) | 39,231 (78.5%) | <0.001 |
| Diabetes mellitus | 31,722 | 1761 (5.5%) | 3704 (11.7%) | 26,257 (82.8%) | <0.001 |
| Asthma | 16,594 | 1247 (7.5%) | 2728 (16.4%) | 12,619 (76.1%) | 0.966 |
| COPD | 5996 | 312 (5.2%) | 723 (12.1%) | 4961 (82.7%) | <0.001 |
| Cystic fibrosis | 41 | 4 (9.8%) | 4 (9.8%) | 33 (80.5%) | <0.001 |
| Cirrhosis | 621 | 45 (7.2%) | 80 (12.8%) | 496 (80%) | <0.001 |
| Smoker | 54,092 | 3120 (5.8%) | 9944 (18.4%) | 41,028 (75.8%) | <0.001 |
| Former smoker | 42,245 | 2126 (5%) | 5648 (13.4%) | 34,471 (81.6%) | <0.001 |
| Cardiac disease 1 | 23,164 | 1161 (5%) | 2450 (10.6%) | 19,553 (84.4%) | <0.001 |
| Hypertension | 51,516 | 2408 (4.7%) | 5001 (9.7%) | 44,107 (85.6%) | <0.001 |
| CVA | 9851 | 636 (6.5%) | 1241 (12.6%) | 7974 (80.9%) | <0.001 |
| Malignancy 2 | 20,965 | 906 (4.3%) | 2111 (10.1%) | 17,948 (85.6%) | <0.001 |
| Chronic renal failure | 7136 | 442 (6.2%) | 951 (13.3%) | 5743 (80.5%) | <0.001 |
| Solid organ transplantation | 7900 | 287 (3.6%) | 687 (8.7%) | 6926 (87.7) | <0.001 |
| Bone marrow transplantation | 279 | 13 (4.7%) | 32 (11.4%) | 234 (83.9%) | 0.0081 |
| Down syndrome | 1466 | 92 (6.3%) | 244 (16.6%) | 1130 (77.1%) | <0.001 |
| Hematologic diseases 3 | 51 | 7 (13.7%) | 11 (21.6%) | 33 (64.7%) | <0.001 |
| Neurologic diseases 4 | 7102 | 598 (8.4%) | 1069 (15.1%) | 5435 (76.5%) | <0.001 |
| Depression | 16,466 | 965 (5.9%) | 2270 (13.8%) | 13,231 (80.3%) | <0.001 |
| Rheumatologic diseases 5 | 4323 | 205 (4.7%) | 519 (12%) | 3599 (83.3%) | <0.001 |
| Biological therapy 6 | 962 | 45 (4.7%) | 107 (11.1%) | 810 (84.2%) | <0.001 |
| Steroid therapy 7 | 145 | 23 (15.9%) | 27 (18.6%) | 95 (65.5%) | <0.001 |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident. 1 Cardiac diseases: including ischemic heart disease, congestive heart failure, and cardiomyopathy. 2 Malignancy: patients treated due to malignancy in the previous five years, including patients with multiple myeloma. 3 Hematologic diseases: including thalassemia major and sickle cell anemia. 4 Neurologic diseases: including Alzheimer’s disease, dementia, Parkinson’s disease, and multiple sclerosis. 5 Rheumatologic diseases: including psoriatic arthritis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma (systemic sclerosis), and dermatomyositis. 6 Biological therapy: including alemtuzumab, adalimumab, certolizumab, infliximab, etanercept, rituximab, and anakinra. 7 Steroid therapy: including prednisone or prednisolone at a dosage of ≥20 mg/day for at least one week.